Moving CAR-T To Earlier Myeloma Lines

Written by The Life Science Feed Editorial Team · Published 1 June 2026 · Edited by Sarah Mitchell

KEY TAKEAWAYS

- Cilta-cel (CARTITUDE-1): 97% ORR, 67% CR in triple-class refractory myeloma; CARTITUDE-4 supports second-line use over standard therapy
- Ide-cel (KarMMa): 73% ORR, 33% CR in triple-class refractory disease - first approved BCMA CAR-T
- Antigen escape (BCMA downregulation) is the primary resistance mechanism - addressed by sequential GPRC5D (talquetamab) and FcRH5 (cevostamab) targeting
- CAR-T is moving earlier in myeloma - CARTITUDE-4 approval in second line challenges the traditional role of autologous SCT

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Munshi NC et al. KarMMa. N Engl J Med. 2021;384:705-716
2. 2. Berdeja JG et al. CARTITUDE-1. Lancet. 2021;398:314-324
3. 3. San-Miguel J et al. CARTITUDE-4. N Engl J Med. 2023;388:1002-1014
4. 4. Moreau P et al. MonumenTAL-1. N Engl J Med. 2022;387:495-505

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com